Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: A rapid review and meta-analysis

Ng, Jay Shen; Hamilton, Daniel G

doi:10.1177/09691413221101807

Cited by 27 publications

(36 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the OSNA method gave us a clear status of axillary diagnosis, even if, for this type of tumour, there is no indication, other than theoretical, for axillary dissection. Therefore, the OSNA procedure allowed the best use to be made of the operating spaces available, with several surgeries that can be performed in the same session [ 23 , 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Axillary Treatment Management in Breast Cancer during COVID-19 Pandemic (Association between ACOSOG Z0011 Criteria and OSNA Test)

Anedda

Cappellacci

Canu

et al. 2023

JPM

View full text Add to dashboard Cite

The outbreak of the SARS-COVID-2 pandemic (COVID-19) had a significant effect on the organisation of healthcare systems. Surgical units saw a significant reduction in the volume of surgical procedures performed, with lengthening waiting lists as a consequence. We assessed the surgical activity in relation to breast cancer that took place at the University Hospital of Cagliari, Italy, from February 2018 to March 2022. Two phases were identified based on the epidemiological circumstances: Phase 1—February 2018 to February 2020; Phase 2—March 2020 to March 2022. The surgery performed in the two phases was then compared. All the patients in our sample underwent a breast surgical procedure involving a lymph node biopsy using OSNA associated with the ACOSOG Z0011 criteria. In the study period overall at our facility, there were 4214 procedures, 417 of which involved breast surgery. In Phase 2, 91 procedures were performed using the OSNA method and ACOSOG Z0011 criteria, enabling the intraoperative staging of axillary nodes. Axillary treatment in breast cancer using this approach resulted in a significant reduction in the number of reoperations for the radicalisation of metastatic sentinel lymph nodes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…There was a difference in the procedures carried out in Phase 2 (more mastectomies and fewer quadrantectomies). This was because patients did not have easy access to hospital facilities or faced delays [ 23 , 25 , 26 ]. Moreover, it was not possible to conduct screening, leading to disease progression [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Axillary Treatment Management in Breast Cancer during COVID-19 Pandemic (Association between ACOSOG Z0011 Criteria and OSNA Test)

Anedda

Cappellacci

Canu

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Throughout most of the world, the mammography screening programmes were paused at the start of the pandemic. This led to marked reductions in breast cancer screening at the start of the pandemic in many other countries worldwide (2-6). In Denmark, the mammography screening programme continued throughout the pandemic and the situation in Denmark is therefore unique and few studies are comparable to our study.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, in Denmark the mammography screening programme continued -and invitations and reminders were sent out -throughout the pandemic since early detection of cancer was considered of high priority. Studies from other countries have shown marked reductions in breast cancer screening during the pandemic as a result of the temporary closures of the screening programmes (2)(3)(4)(5)(6); however, the participation in mammography screening in Denmark with a continuation of the programme has not yet been described.…”

Section: Introductionmentioning

confidence: 99%

Nation-wide mammography screening participation in Denmark during the COVID-19 pandemic: An observational study

Olesen¹,

Jensen²,

Møller³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background In most of the world, the mammography screening programmes were paused at the start of the pandemic, whilst mammography screening continued in Denmark. We examined the mammography screening participation during the COVID-19 pandemic in Denmark. Methods The study population comprised all women aged 50-69 years old invited to participate in mammography screening from 2016-2021 in Denmark based on data from the Danish Quality Database for Mammography Screening in combination with population-based registries. Using a generalised linear model, we estimated prevalence ratios (PR) and 95% confidence intervals (CI) of mammography screening participation within 90, 180 and 365 days since invitation during the pandemic in comparison with the previous years adjusting for age, year and month of invitation. Results The study comprised 1,828,791 invitations among 847,766 women. Before the pandemic, 80.2% of invitations resulted in participation in mammography screening within 90 days, 82.7% within 180 days and 83.1% within 365 days. At the start of the pandemic, the participation in screening within 90 days was reduced to 69.9% for those invited in pre-lockdown and to 76.5% for those invited in 1st lockdown. Extending the length of follow-up time to 365 days only a minor overall reduction was observed (PR=0.94; 95% CI: 0.93-0.95 in pre-lockdown and PR=0.97; 95% CI: 0.96-0.97 in 1st lockdown). A lower participation was; however, seen among immigrants and among women with a low income. Conclusions The short-term participation in mammography screening was reduced at the start of the pandemic, whilst only a minor reduction in the overall participation was observed with longer follow-up time indicating that women postponed screening. Some groups of women; nonetheless, had a lower participation indicating that the social inequity in screening participation was exacerbated during the pandemic. Funding The study was funded by the Danish Cancer Society Scientific Committee (grant number R321-A17417) and the Danish regions.

show abstract

“…Indeed, reviews showed that countries that implemented lockdowns measures showed the highest reduction in number of new cancer cases being diagnosed. Breast cancer diagnosis rates dropped by an estimate between 18-29% between 2019 and 2021 42 .…”

Section: Reduced Cancer Diagnosismentioning

confidence: 99%

Changes in cancer prevention and management and patient needs during the COVID-19 pandemic: An umbrella review of systematic reviews

Muka

Farahani

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: The COVID-19 pandemic led to relocation and reconstruction of health care resources and systems, and to a decrease in healthcare utilization, and this may have affected the treatment, diagnosis, prognosis, and psychosocial well-being of cancer patients. Objective: To summarize and quantify the evidence on the impact of the COVID-19 pandemic on the full spectrum of cancer care. Methods: We performed an umbrella review to summarize and quantify the findings from systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations; delays or cancellations in screening and diagnosis; psychosocial well-being, financial distress, and use of telemedicine as well as on other aspects of cancer care. PubMed was searched for relevant systematic reviews with or without meta-analysis published before November 29th, 2022. Abstract, full text screening and data extraction were performed by two independent reviewers. AMSTAR-2 was used for critical appraisal of included systematic reviews. Results. 45 systematic reviews evaluating different aspects of cancer care were included in our analysis. Most reviews were based on observational studies judged to be at medium and high risk of bias. Only 2 of the included reviews had high or moderate scores based on AMSTAR-2. Findings suggest treatment modifications in cancer care during the pandemic versus the pre-pandemic period were based on low level of evidence. Different degrees of delays and cancellations in cancer treatment, screening and diagnosis were observed, with low-and-middle income countries and countries that implemented lockdowns being disproportionally affected. A shift from in-person appointments to telemedicine use was observed, but utility of telemedicine, challenges in implementation and cost-effectiveness in different areas of cancer care were little explored. Evidence was consistent in suggesting psychosocial well-being (e.g., depression, anxiety, and social activities) of cancer patients deteriorated, and cancer patients experienced financial distress, albeit results were in general not compared to pre-pandemic levels. Impact of cancer care disruption during the pandemic on cancer prognosis was little explored. Conclusion: Substantial but heterogenous impact of COVID-19 pandemic on cancer care has been observed. Evidence gaps exist on this topic, with mid- and long-term impact on cancer care being most uncertain.

show abstract

Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: A rapid review and meta-analysis

Cited by 27 publications

References 62 publications

Axillary Treatment Management in Breast Cancer during COVID-19 Pandemic (Association between ACOSOG Z0011 Criteria and OSNA Test)

Axillary Treatment Management in Breast Cancer during COVID-19 Pandemic (Association between ACOSOG Z0011 Criteria and OSNA Test)

Nation-wide mammography screening participation in Denmark during the COVID-19 pandemic: An observational study

Changes in cancer prevention and management and patient needs during the COVID-19 pandemic: An umbrella review of systematic reviews

Contact Info

Product

Resources

About